Hairy-cell leukemia is a B-cell tumor in which IFN-~has recently been shown to have a clear antitumor effect. In order to elucidate the action of IFN in HCL we studied the the effect of human recombinant IFN-alpha-2 on purified peripheral blood hairy cells and a hairy cell leukemia line(HCL-1). Since IFN can promote cell differentiation of various tumor cell lines, morphological and immunophenotypic differentiating effects were studied in detail. In the presence of IFN-~ the leukemic hairy cells lost most of their typical villous membrane projections and became nonadherent to glass and plastic surfaces. Surface marker analysis was carried out using the monoclonal antibodies FMC-7, OKlal, Leu-M3, anti-Tac, T015, BMA 030, and Lyt3, Reactivity with the monoclonals Lyt3 and BMA 030 was found to be induced by IFN. In contrast, IL-2 receptor expression was down-regulated by IFN treatment. From these results we conclude that IFN-alpha-2 exerts a profound differen tiating action on hairy cells in vitro. During a study on the effect of human-alpha-interferon in 13 pts. with chronic granulocytic leucemia we analysed the nephrotoxic potential of this agent. As partieularl~ sensitive parameters in the detection of subclinical renal injury we measured the excretion of the following 5 enzymes : Lactate Dehydrogenase (LDH), Leucinarylamidase (LAP), Gamma-Glutamyltranaferase (GGT), Beta-Galactosidase (GAL), N-Acetylglucoaaminfdase (NAG). Additionally we analysed the protein e• and the urinary sediment. In i0 of 13 pts. there was a significant increase in the excretion of LDH, LAP, GGT~and NAG; 6 pts. had a rise in the output of G~L, 6 pts. developed a proteinuria. According to our results in pts. with malignant lymphomaS we must conclude that human-alpha-interferon is nephrotoxic in leucemia and related disorders. To date we have no explanation of the pathogenesis of the observed phenomena. But our results should lead to special attention on renal function studies in pts. treated with human-alpha-interferon. Further studies are warranted to find out whether preventive steps are necessary.
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Comparison Thirteen patients (pts) with HCL have been treated with yand/or ~2B-IFN. Pretreatment and follow-up evaluations included complete blood counts; staining with acid phosphatase resistant to tartrate; determination of liver and renal functions, LDH levels, serum electrolytes, clotting factors; bone marrow biopsy. To date, II pts -ID men; median age 49 years (range 36-73); 22 months (range 2-49) after diagnosis -are evaluable for response. In 6 pts, treatment was started with y-IFN (initial dose 4xIDbU/m ~ sc every second day) lasting 2-7 months (median 5.5). Although the white blood cel~ counts slightly decreased durin~ therapy from 3.3z49x10 /l (median 23xi09) to 1.5-43x I0~/I (median 8.4x109), no remission was obtained: median lymphocytes 89% vs 87%, 90% hairy cells (HC); median hemoglobin (Hb) levels 10.3 g% vs 11.1 g%; median platelet counts lllx109/l (range 21-179xI0 ~) vs 145xi09/I (range 30-247xi09); in bone marrow biopsies no decrease of HC. IFNc2B (initial dose 1-4x106U/m 2) was given to 5/6 ptS pretreated with y~IFN and another 5 pts without [FN pretreatmerit {splenectomy n=3, chemotherapy n=~). Dependent o~ the duration of treatment (2-8 months, median 4), there are so far: CR I, PR 4, ~R 5, SD I (median blood cell counts: leukocytes 4.2x10~/I, 51% lymphocytes; platelets 190x109/I; Hb 12.2 g%; absence or decrease of HC in bone marrow biopsies of 5 pts). Side effects including fever, headache, nausea, myalgia, dryness of the mouth, and fatigue were severe only during the first days of therapy and did not differ significantly between the two IFN preparations.
In conclusion, IFN-y is unlikely to have any significant impact on the course of HCL, while IFN-~2B does mesult in improvement of hematologic values and feelings of wellbeing in almost all patients.
Innere Universit~tsklinik und Poliklinik (Tumorforschung), Hufelandstra3e 55, D-43go Essen I. The results of the treatment of mycosis fungoides by alpha-interferon are inconsistent. Synergistic effects of interferon with vinca alkaloids against human tumors have been suggested in clonogenic assay systems. Thus, we have initiated the treatment of patients with mycosis fungmides with Hoffmann-La Roche recombinant leukocyte alpha-A interferon and vinblastine in a phase I/IT study to test antltumor effects and tolerance.
Int 06 TREATMENT OF MYCOSIS FUNGOIDES BY RECOMBINANT LEUKOCYTE
Since 2/84 six patients received recombinant leukocyt~ alpha-A interferon i.m. from a starting dose of 3} lO m IU on day l, to 9xlO ~ IU on day 2, and up to lOxlO ~IU/m z the following days for 12 weeks, followed by lOxlO 6 IU/m 2 x3/week. In addition, vinblastine was administered i.v. once every three weeks from 0.05 to a maximum of 0.15 mg/kg.
Responses were seen in 5/6 patients: one complete response for five weeks which could not be maintained because of patient's rejection, three partial responses (5, 14, 49 weeks), and one minor response (5 weeks), respectively.
Except one patient who developed hypotonia and an acute toxic state with coma causing discontinuation of therapy, side effects were mild or moderate. Flu like symptoms were seen in all patients during initiation of therapy and could effectively be suppressed by acetaminophen. One patient was found to have elevated transaminases. After recovery he refused further treatment in complete remission.
In conclusion, combined treatment by recombinant leukocyte alpha-A interferon and vinblastine appears to be an effective regime in patients with mycosis fungoides. Further studies with a reduced interferon-dose are projected to decrease the side effects without reduction of antitumor efficacy.
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